Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Editors Pick
    • New vaccine for...

    New vaccine for Clostridioides difficile infection coming up, indicate results from clinical trial

    Written by Medha Baranwal Baranwal Published On 2019-06-05T20:15:09+05:30  |  Updated On 5 Jun 2019 8:15 PM IST
    New vaccine for Clostridioides difficile infection coming up, indicate results from clinical trial

    The findings from a recent phase 2 clinical trial found an investigational Clostridioides difficile vaccine to be safe, well-tolerated and immunogenic in healthy seniors aged 65 to 85 years.


    Clostridium difficile is a gram-positive bacterium that is a major cause of nosocomial diarrhea worldwide. Symptoms of C. difficile infection (CDI) range from mild diarrhea to severe outcomes, including pseudomembranous colitis, toxic megacolon, intestinal perforation, and even death. Rates of CDI significantly increased in recent years, owing largely to the emergence of highly virulent, fluoroquinolone-resistant polymerase chain reaction–ribotype 027 strains.


    The study, published in the journal Clinical Infectious Diseases, is significant as currently there are no available vaccines for the prevention of C. difficile infection (CDI). The Pfizer vaccine contains genetically and chemically detoxified toxins A and B, and designed to induce high levels of C. difficile toxin-neutralizing antibodies.


    The vaccine, PF-06425090, which has already entered a phase 3 trial, was found to be immunogenic when administered to healthy adults aged 65 to 85 years at either 100- or 200-μg dose levels, delivered at 0, 1, and 6 months or 1, 8, and 30 days.


    Shon A. Remich, senior director of vaccine clinical research and development at Pfizer, and colleagues conducted this phase 2, placebo-controlled, randomized, observer-blinded study. The study involved analysis of 855 healthy adults, aged 65 to 85 years, from July 2015 through March 2017. Participants were randomly assigned to receive the investigational vaccine in either a 100-g or 200-g dose or placebo at 0, 1 and 6 months (the “month regimen”), or 1, 8 and 30 days (the “day regimen”).


    Key findings:




    • For both regimens, the researchers observed a higher immune response among participants who received the 200-g dose compared with participants receiving the 100-g dose.

    • The month regimen demonstrated stronger and more persistent immune responses compared with the day regimen, and those responses remained elevated 12 months after the third dose.

    • Responses for the month regimen peaked at month 7, whereas responses for the day regimen peaked at day 37.

    • Participant-reported local reactions occurred more frequently among participants who received the vaccine compared with controls, but the rates of systemic events were similar across the groups.

    • Those assigned to the day regimen reported more related adverse events compared with those on the month regimen.


    “The results of the phase 2 trial support continued development of the vaccine candidate,” Remich said.


    For a detailed study follow the link: https://doi.org/10.1093/cid/ciz153
    C difficile infectionClinical Infectious DiseasesClinical trialClostridioides difficile infectionClostridioides difficile vaccinediarrheadrug safetyimmunogenicInfectionsintestinal perforationnew vaccinenosocomial diarrheapfizerphase 2 trialpseudomembranous colitistoxic megacolonVaccine

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medha Baranwal Baranwal
    Medha Baranwal Baranwal
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok